26.21
0.14 (0.54%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Rapport Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | -0.5 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.5 |
| 技术平均移动指标 参考 | 2.5 |
| 聪明钱 30% | 1.6 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | 4.0 |
| 市场环境 | ×0.79 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.5% |
| 支柱一致性 | ×0.98 |
| 不计入评分 | |
| 价格波动 参考 | 4.8 |
| 最终评分 | 0.24 |
|
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 6.28% |
| 机构持股比例 | 105.23% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HEALY JAMES | 22.50 | - | 969,480 | 21,813,300 |
| THIRD ROCK VENTURES V, L.P. | 25.05 | - | 1,428,571 | 35,785,704 |
| 累积净数量 | 2,398,051 | |||
| 累积净值 ($) | 57,599,004 | |||
| 累积平均购买 ($) | 24.02 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| THIRD ROCK VENTURES V, L.P. | 董事 | 30 Oct 2026 | 获得 (+) | 238,095 | 25.05 | 5,964,280 |
| THIRD ROCK VENTURES V, L.P. | 董事 | 30 Oct 2026 | 获得 (+) | 1,190,476 | 25.05 | 29,821,424 |
| HEALY JAMES | 董事 | 28 Oct 2026 | 买 (+) | 969,480 | 22.50 | 21,813,300 |
投资组合